Lower Left Ventricular Ejection Time in <i>MYBPC3</i> Variant Carriers with Overt or Subclinical Hypertrophic Cardiomyopathy
The data suggest that variants in MYBPC3 and MYH7 result in distinct biophysical consequences, which can be detected by measuring LVETI in patients. The findings may have implications for potential genotype-specific differences in response to therapies targeting sarcomere function.
Authors
- Carolyn Yung Ho (ORCID: https://orcid.org/0000-0002-7334-7924)
- Thomas Eschenhagen (ORCID: https://orcid.org/0000-0003-1750-1170)
- Paulus Kirchhof (ORCID: https://orcid.org/0000-0002-1881-0197)
- Isabell Yan (ORCID: https://orcid.org/0000-0002-7343-2205)
- Julia Münch (ORCID: https://orcid.org/0000-0001-6288-7389)
- Rixa Woitschach
- Monica Patten (ORCID: https://orcid.org/0000-0003-1751-1731)
- Daniel Reichart (ORCID: https://orcid.org/0000-0002-8559-5888)
- Fanny Kortüm
- Lucie Carrier
- Zoe Möhring
Institutions
- Brigham and Women's Hospital (US)
- Universität Hamburg (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- German Centre for Cardiovascular Research (DE)
- Institute of Experimental Pharmacology and Toxicology of the Slovak Academy of Sciences (SK)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- ESC Heart Failure
- Published
- 2025-07-04
- DOI
- https://doi.org/10.1002/ehf2.15346
- Citations
- 1
- Primary Topic
- Cardiomyopathy and Myosin Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- Pfizer
- BioMarin Pharmaceutical
- Deutsches Zentrum für Herz-Kreislaufforschung
- Cytokinetics
- British Heart Foundation
- Deutsche Forschungsgemeinschaft
- Fondation Leducq
- National Institutes of Health
- National Heart, Lung, and Blood Institute